Biotech Values

[DewDiligence]

SBPH reverse-merges into—(private)—F-star Therapeutics:

https://finance.yahoo.com/news/spring-bank-pharmaceuticals-f-star-202700605.html

The combined company…will advance [F-star’s] immuno-oncology pipeline of multiple tetravalent bispecific antibody programs, as well as Spring Bank’s STING (STimulator of INterferon Gene) agonist, SB 11285, currently in a Phase 1/2 clinical trial.

…Following closing, which is expected to occur in late 2020, Spring Bank will be re-named F-star Therapeutics, Inc. and is expected to trade on the Nasdaq Capital Market under the ticker symbol “FSTX”.

…On a pro forma basis and assuming that the proceeds of the concurrent F-star financing will be $25 million, current Spring Bank equity holders and F-star equity holders will own approximately 38.8% and 61.2%, respectively, of the combined company calculated on a fully diluted basis…